By Josh Beckerman

 

Gilead Sciences Inc.'s remdesivir, commonly used to treat hospitalized Covid-19 patients, has received Food and Drug Administration approval for some non-hospitalized patients.

Gilead said the expanded indication allows the drug to be administered in qualified outpatient settings that can provide daily intravenous infusions over three consecutive days.

The FDA also expanded the pediatric emergency use authorization to include non-hospitalized pediatric patients younger than 12 who are at high risk of disease progression.

Gilead said "while we continue to advance remdesivir to benefit more patients in multiple settings, we are also advancing our investigational oral compounds. These are based on the same antiviral mechanism of action as remdesivir and a Phase 1 trial for our oral COVID-19 antiviral, GS-5245 is now under way."

 

Write to Josh Beckerman at josh.beckerman@wsj.com

 

(END) Dow Jones Newswires

January 21, 2022 19:01 ET (00:01 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Gilead Sciences Charts.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Gilead Sciences Charts.